AI Article Synopsis

  • Chemotherapy and immunotherapy, specifically durvalumab, are the standard treatment for advanced small-cell lung cancer (SCLC), but can lead to rare side effects called immune-related adverse events (irAEs), notably affecting bones.
  • This case details a 54-year-old female SCLC patient who, after three months of durvalumab treatment, showed osteoblastic bone changes on imaging that mimicked metastasis, despite having no prior bone issues.
  • The accurate diagnosis of these bone changes as irAEs, not metastasis, emphasizes the need for careful evaluation in similar cases, particularly through methods like pathological biopsy to avoid misdiagnosis.

Article Abstract

Background: Chemotherapy combined with immunotherapy is currently the standard first-line treatment for advanced small-cell lung cancer (SCLC). Immunotherapy can induce specific adverse events, called immune-related adverse events (irAEs). IrAEs of bones have rarely been reported. However, identifying bone irAEs could be important in avoiding misdiagnosis and ensuring appropriate patient management. This is the first report describing the diagnosis of irAEs of osteoblastic bone changes mimicking bone metastasis in a SCLC patient treated with durvalumab.

Case Description: In this report, we describe a unique and challenging case in which a 54-year-old female patient with SCLC treated with durvalumab, an immunotherapy drug, exhibited osteoblastic bone changes that appeared similar to bone metastasis on imaging but were actually a side effect of immunotherapy. Before treatment, imaging revealed no bone metastasis. In the third month after treatment with durvalumab, computed tomography (CT) revealed multiple bone alterations, predominantly osteoblastic lesions with minor osteolytic changes. Various imaging tests suggested bone metastasis, but she had no symptoms related to bone disease. Notably, the lesions in the chest had achieved a partial response. Based on a comprehensive analysis of the CT-guided pathological biopsy results, the patient's symptoms, and the biological characteristics of SCLC, we determined that these bone changes were irAEs occurring in the skeletal system. The patient was followed up for 10 months, during which time the bone lesions remained stable.

Conclusions: IrAEs of bones are rare, and their manifestations vary. Sometimes, the imaging manifestations of bone irAEs are difficult to distinguish from bone metastasis. If patients show variable treatment responses between different lesions, careful evaluation (including a pathological biopsy) is necessary.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384499PMC
http://dx.doi.org/10.21037/tlcr-24-461DOI Listing

Publication Analysis

Top Keywords

bone metastasis
24
bone
15
osteoblastic bone
12
bone changes
12
bone alterations
8
mimicking bone
8
small-cell lung
8
lung cancer
8
patient treated
8
treated durvalumab
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!